

May 18, 2026  
SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director  
President and Chief Executive Officer  
(Securities Code: 4582)

## **SymBio Establishes Stable Supply Framework for Ultra-High-Sensitive (Pico-Level) Immunochromatography System**

Tokyo, Japan, May 18, 2026 – SymBio Pharmaceuticals Limited (hereinafter "SymBio" or the "Company") today announced that it has entered into master supply agreements with Nippon Steel Chemical & Material Co., Ltd. ("Nippon Steel C&M") and Nippon Gene Co., Ltd. ("Nippon Gene") for SymBio's ultra-high-sensitive immunochromatography system (the "IVD System") currently under development. Under these agreements, Nippon Steel C&M will supply the foundational nano-composite particles for the IVD System, while Nippon Gene will manufacture the ultra-high-sensitivity test kits.

Going forward, SymBio will collaborate with both partners to accelerate the development and commercialization of the IVD System. By securing these strategic supply agreements, SymBio has established a stable supply chain to advance the development of the business.

The IVD System is an innovative Point-of-Care Testing (POCT) technology capable of quantitatively detecting antigens, including viruses, at concentrations below 1 picogram/mL (less than one-trillionth of a gram per mL) at the point of care and in real time. SymBio and Nippon Steel C&M jointly obtained a patent for this technology in October 2025, and global patent applications are currently progressing under the Patent Cooperation Treaty (PCT). Beyond viral infectious diseases, the IVD System is expected to enable early diagnosis and intervention in oncology and central nervous system disorders, including Alzheimer's disease.

Statement from Fuminori Yoshida, President and CEO: "We are delighted to have established a stable supply framework through our partnership with both companies. We believe that the ultra-high-sensitivity POCT system will be a game changer and will address diverse social needs around the world."

The Company does not expect this matter to have a material impact on its consolidated financial results for the fiscal year ending December 2026.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125

---

Notes

**POCT (Point of Care Testing)**

A rapid test performed on site to support early diagnosis and treatment.

**SymBio Pharmaceuticals' IVD (in vitro diagnostic) business**

Reference: “Patent Obtained for a Groundbreaking Immunoassay with Ultra-High Sensitivity (detection at one part in a trillion)” (Press release issued October 20, 2025)

SymBio's mission is to address unmet medical needs, and it positions its IVD business as an “undeserved therapeutic areas,” contributing to precision medicine for patients.

With this IVD System, SymBio aims to create a technological foundation that fundamentally transforms the existing testing market. In the medical field, it can be used not only in outpatient clinics and hospital wards, but also at emergency care sites, enabling testing and diagnosis on the spot, and making it possible to diagnose viral infections at an early stage, which is currently difficult.

The IVD System is also expected to target not only viral infectious diseases, but also oncology and central nervous system disorders, including Alzheimer's disease. In non-medical fields, it is also expected to contribute to agriculture such as seeds and vegetables, as well as areas where damage from invasive species has become a serious issue.

The progress of the IVD business currently under preparation requires expertise and infrastructure in specialized areas such as diagnostic technology, manufacturing, and

quality control. For this reason, SymBio's core strategy is to promote business development through partnerships with optimal partners in each field.

#### **Value Delivered by the IVD System**

- **Early Clinical Diagnosis:**  
Enables early antigen detection for diseases in viral infectious diseases, oncology, and central nervous system disorders such as Alzheimer's disease
- **On-site Responsiveness:**  
Rapid and accurate testing in both clinical and non-clinical settings
- **Market Creation:**  
Development of a new market for ultra-high-sensitivity (pico-level) quantitative antigen testing
- **Non-medical Applications:**  
Enables rapid, on-site antigen testing for agricultural quality control and environmental monitoring